{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 458270329
| image =  
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = zu/o
| target = [[carcinoembryonic antigen]]
<!-- Clinical data -->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 219649-07-7
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08936
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| chemical_formula =  
| molecular_weight =  
}}

'''Labetuzumab''' (marketed under the trade name '''CEA-CIDE''') is a [[humanized]] [[IgG1]] [[monoclonal antibody]] for the treatment of [[colorectal cancer]].<ref>[http://www.ama-assn.org/ama/upload/mm/365/labetuzumab1.doc Statement On A Nonproprietary Name Adopted By The Usan Council - Labetuzumab], ''American Medical Association''.</ref> It selectively binds to carcinoembryonic cell adhesion molecule 5. <ref>http://www.cancer.gov/drugdictionary?cdrid=692828</ref>

This drug was developed by [[Immunomedics]], Inc.

==References==
<references/>

{{Monoclonals for tumors}}

[[Category:Monoclonal antibodies for tumors]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}